SURPASS J-combo study comparing people with T2DM in a Japanese population with a high HbA1c on oral antihyperglycemic monotherapy on 5, 10, or 15 mg of once weekly tirzepatide for 52 weeks showed an improvement of glycemic and lipid control, weight loss and reduction in blood pressure [57]
Another meta-analysis, which looked at relevant data from multiple clinical studies, estimated that 40-70% of people on GLP-1 drugs will experience nausea at some point while taking the medication
During these check-ins, we: Track your progress Adjust your plan if needed Encourage you when you feel low If you face a setback, we guide you on how to recover instead of giving up
Multi-specific peptides have emerged as promising therapeutic strategies for clinical weight loss
References: EMC SmPC Ozempic (semaglutide)
Early-phase clinical data suggest this combination may also have beneficial effects on liver fat content, lipid profiles, and blood glucose control, though these observations require confirmation in larger, longer-duration studies